ASP3662 clinical trials
Also written SPI-62 and ASP3662.
How each study uses ASP3662 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ASP3662 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Sparrow Pharmaceuticals (7) · Astellas Pharma Global Development, Inc. (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ASP3662 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)RecruitingPhase 2Sparrow PharmaceuticalsNCT07296484Written as clofutriben
- Clofutriben Pharmacokinetics in Patients With Impaired Renal FunctionRecruitingPhase 1Sparrow PharmaceuticalsNCT07227922Written as 12mg clofutriben
- SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal TumorCompletedPhase 2Sparrow PharmaceuticalsNCT05436639Written as SPI-62 dose
- SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's SyndromeCompletedPhase 2Sparrow PharmaceuticalsNCT05307328Written as SPI-62
- A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)TerminatedPhase 1Sparrow PharmaceuticalsNCT06281236Written as SPI-62
- A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR)CompletedPhase 2Sparrow PharmaceuticalsNCT05436652Written as SPI-62
- A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62CompletedPhase 1Sparrow PharmaceuticalsNCT05409027Written as SPI-62
- Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral NeuropathyTerminatedPhase 2Astellas Pharma Global Development, Inc.NCT02372578Written as ASP3662
- A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662CompletedPhase 1Astellas Pharma Global Development, Inc.NCT02194491Written as ASP3662